Please use this identifier to cite or link to this item:
|Publication type:||Article in scientific journal|
|Type of review:||Peer review (publication)|
|Title:||Cost-utility analysis of thumb carpometacarpal resection arthroplasty : a health economic study using real-world data|
Herren, Daniel B.
|Published in:||Journal of Hand Surgery (American Volume)|
|Publisher / Ed. Institution:||Elsevier|
|Subjects:||Cost-effectiveness; Cost-utility; Quality of life; Thumb carpometacarpal osteoarthritis|
|Subject (DDC):||362.1041: Health economics |
617.5: Orthopaedic surgery
|Abstract:||Purpose: Knowledge about the costs and benefits of hand surgical interventions is important for surgeons, payers, and policy makers. Little is known about the cost-effectiveness of surgery for thumb carpometacarpal osteoarthritis. The objective of this study was to examine patients’ quality of life and economic costs, with focus on the cost-utility ratio 1 year after surgery for thumb carpometacarpal osteoarthritis compared with that for continued nonsurgical management. Methods: Patients with thumb carpometacarpal osteoarthritis indicated for resection arthroplasty were included in a prospective study. The quality of life (using European Quality of Life-5 Dimensions-5 Level), direct medical costs, and productivity losses were assessed up to 1 year after surgery. Baseline data at recruitment and costs sustained over 1 year before surgery served as a proxy for nonsurgical management. The total costs to gain 1 extra quality-adjusted life year and the incremental cost-effectiveness ratio were calculated from a health care system and a societal perspective. Results: The mean European Quality of Life-5 Dimensions-5 Level value for 151 included patients improved significantly from 0.69 to 0.88 (after surgery). The productivity loss during the preoperative period was 47% for 49 working patients, which decreased to 26% 1 year after surgery. The total costs increased from US $20,451 in the preoperative year to US $24,374 in the postoperative year. This resulted in an incremental cost-effectiveness ratio of US $25,370 per quality-adjusted life year for surgery compared with that for simulated nonsurgical management. Conclusions: The calculated incremental cost-effectiveness ratio was clearly below the suggested Swiss threshold of US $92,000, indicating that thumb carpometacarpal surgery is a cost-effective intervention.|
|Fulltext version:||Accepted version|
|License (according to publishing contract):||CC BY-NC-ND 4.0: Attribution - Non commercial - No derivatives 4.0 International|
|Departement:||School of Management and Law|
|Organisational Unit:||Winterthur Institute of Health Economics (WIG)|
|Appears in collections:||Publikationen School of Management and Law|
Files in This Item:
|2022_Grobet-etal_Cost-utility-analysis-thumb-carpometacarpal.pdf||525.28 kB||Adobe PDF|
Show full item record
Grobet, C., Audigé, L., Eichler, K., Meier, F., Marks, M., & Herren, D. B. (2022). Cost-utility analysis of thumb carpometacarpal resection arthroplasty : a health economic study using real-world data. Journal of Hand Surgery (American Volume), 47(5), 445–453. https://doi.org/10.1016/j.jhsa.2022.01.013
Grobet, C. et al. (2022) ‘Cost-utility analysis of thumb carpometacarpal resection arthroplasty : a health economic study using real-world data’, Journal of Hand Surgery (American Volume), 47(5), pp. 445–453. Available at: https://doi.org/10.1016/j.jhsa.2022.01.013.
C. Grobet, L. Audigé, K. Eichler, F. Meier, M. Marks, and D. B. Herren, “Cost-utility analysis of thumb carpometacarpal resection arthroplasty : a health economic study using real-world data,” Journal of Hand Surgery (American Volume), vol. 47, no. 5, pp. 445–453, 2022, doi: 10.1016/j.jhsa.2022.01.013.
Grobet, Cécile, et al. “Cost-Utility Analysis of Thumb Carpometacarpal Resection Arthroplasty : A Health Economic Study Using Real-World Data.” Journal of Hand Surgery (American Volume), vol. 47, no. 5, 2022, pp. 445–53, https://doi.org/10.1016/j.jhsa.2022.01.013.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.